Robotic surgery is becoming more common, but the important question is not only whether it works. It is also who is helping surgeons learn to use it—and what else is being measured. Medicines are not the only place where industry payments may shape medical decisions.

Earlier evidence connected drug-company payments with doctors prescribing more, but much less was known about payments from surgical-device companies and the use of robot-assisted surgery. So the study examined the relationship between payments to healthcare providers and the use of robot-assisted surgery.

The study looked at payments from companies that make robotic equipment and how those payments were divided among different purposes. It then compared payments to individual surgeons and hospitals with the use of robotic surgery in general surgery, urology, and gynecology, while also looking at changes over time and differences between regions.

To make the records easier to compare, reported payments were grouped into broad purposes: education and training, travel and food, direct payments, facility costs, and research. The last two groups applied only to teaching hospitals, and ownership or investment payments were left out because that category was added only in twenty nineteen.

From 2015 to 2019, robot-assisted operations became much more common, especially digestive-system operations, while payments to the doctors performing them did not rise clearly. That mismatch suggests expanding use was not simply driven by increasing doctor payments.

Across the study, higher industry payments were associated with higher volumes of robot-assisted surgery. Three quarters of the funding supported education activities and surgeons’ travel to training and conferences, while less than one percent supported research.

Payments were concentrated in large academic health centers, and most went to individual physicians rather than teaching hospitals. The relationship was not a simple story of payments rising every time company revenue rose. As companies’ revenue increased in the United States, the total amount of outgoing payments remained stable.

The study examined the association between payments to providers and robotic-surgery volume, and found a significant positive correlation between payments and the number of robotic procedures performed. The records could not establish cause and effect because payments were reported as yearly totals.

The training also covered surgical skills, safety, and technology use for other healthcare workers and hospital staff, not only surgeons. Hospital mergers and acquisitions mean many surgical training programs now serve multiple hospitals and provide training to a wider pool of providers, including surgeons in rural areas.

The study expects robot-assisted surgery to keep rising as substantial industry payments continue to support physician education and training. Only one point four percent of payments supported comparative research on RAS outcomes, while RAS use is expected to rise and this gap undermines quality improvement and tracking patient safety and provider preferences.

The study found that payments from robotic-device companies and robot-assisted surgery grew together, especially around training, while relatively little funding supported research on patient outcomes. Patients therefore need both access to new tools and independent evidence about their safety and value.